Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

March 25, 2017

Primary Completion Date

March 1, 2018

Study Completion Date

April 12, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

PEGFILGRASTIM

Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.

Trial Locations (2)

Celerion Inc., Lincoln

Celerion Inc., Tempe